Tri Locum Partners LP: AXSOME THERAPEUTICS INC. (AXSM): Quarterly 13F Position History
As of Q2 2026, Tri Locum Partners LP reported 219,308 shares of AXSOME THERAPEUTICS INC. (AXSM), worth $53.7M and representing 6.6% of its 13F equity book. Quarter-over-quarter share count change: + 157,192 (+253.1%) . The position first appeared in Q4 2022 and has been disclosed across 15 13F-HR filings in Pactolio's tracked window.
- 219,308Shares Held (Latest Filing)
- $53.7MReported Market Value (Latest Filing)
- 6.6%Portfolio Weight (% of 13F Equity Book)
- +157,192Quarter-over-Quarter Share Change
- +$43.2MQuarter-over-Quarter Value Change
- 306,513Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 15 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 219,308 | +157,192 | +253.1% | $53.7M | 6.6% | $244.8 |
| Q1 2026 | 62,116 | 139,511 | -69.2% | $10.5M | 1.5% | $169.0 |
| Q4 2025 | 201,627 | 90,510 | -31.0% | $36.8M | 4.8% | $182.6 |
| Q3 2025 | 292,137 | +134,276 | +85.1% | $35.5M | 8.2% | $121.5 |
| Q2 2025 | 157,861 | +56,621 | +55.9% | $16.5M | 5.0% | $104.4 |
| Q1 2025 | 101,240 | 148,529 | -59.5% | $11.8M | 6.1% | $116.6 |
| Q4 2024 | 249,769 | +158,048 | +172.3% | $21.1M | 4.4% | $84.6 |
| Q3 2024 | 91,721 | 214,792 | -70.1% | $8.2M | 2.0% | $89.9 |
| Q2 2024 | 306,513 | +203,802 | +198.4% | $24.7M | 6.2% | $80.5 |
| Q1 2024 | 102,711 | 28,027 | -21.4% | $8.2M | 2.8% | $79.8 |
| Q4 2023 | 130,738 | 11,772 | -8.3% | $10.4M | 5.1% | $79.6 |
| Q3 2023 | 142,510 | 57,570 | -28.8% | $10.0M | 3.2% | $69.9 |
| Q2 2023 | 200,080 | +50,875 | +34.1% | $14.4M | 5.4% | $71.9 |
| Q1 2023 | 149,205 | 50,849 | -25.4% | $9.2M | 2.8% | $61.7 |
| Q4 2022 | 200,054 | – | – | $15.4M | 6.8% | $77.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Tri Locum Partners LP first disclose a AXSM position in 13F-HR filings?
Tri Locum Partners LP first reported AXSOME THERAPEUTICS INC. (AXSM) on its 13F-HR filing for the period ending 2022-12-31 (Q4 2022). The position has appeared on 15 reported quarters within Pactolio's tracked window.
What was Tri Locum Partners LP's most recent quarter-over-quarter share-count change in AXSM?
Between Q1 2026 and Q2 2026, Tri Locum Partners LP added 157,192 shares of AXSM (+253.1%), bringing the total reported position to 219,308 shares at a market value of $53.7M.
Does the implied price-per-share represent Tri Locum Partners LP's cost basis in AXSM?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.